<?xml version='1.0' encoding='utf-8'?>
<document id="20660678"><sentence text="Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers."><entity charOffset="20-29" id="DDI-PubMed.20660678.s1.e0" text="darunavir" /><entity charOffset="30-39" id="DDI-PubMed.20660678.s1.e1" text="ritonavir" /><entity charOffset="44-53" id="DDI-PubMed.20660678.s1.e2" text="rifabutin" /><pair ddi="false" e1="DDI-PubMed.20660678.s1.e0" e2="DDI-PubMed.20660678.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20660678.s1.e0" e2="DDI-PubMed.20660678.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s1.e0" e2="DDI-PubMed.20660678.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s1.e1" e2="DDI-PubMed.20660678.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s1.e1" e2="DDI-PubMed.20660678.s1.e2" /></sentence><sentence text="The drug-drug interaction between rifabutin (RFB) and darunavir/ritonavir (DRV/r) was examined in a randomized, three-way crossover study of HIV-negative healthy volunteers who received DRV/r 600/100 mg twice a day (BID) (treatment A), RFB 300 mg once a day (QD) (treatment B), and DRV/r 600/100 mg BID plus RFB 150 mg every other day (QOD) (treatment C)"><entity charOffset="34-43" id="DDI-PubMed.20660678.s2.e0" text="rifabutin" /><entity charOffset="45-48" id="DDI-PubMed.20660678.s2.e1" text="RFB" /><entity charOffset="54-63" id="DDI-PubMed.20660678.s2.e2" text="darunavir" /><entity charOffset="64-73" id="DDI-PubMed.20660678.s2.e3" text="ritonavir" /><entity charOffset="236-244" id="DDI-PubMed.20660678.s2.e4" text="RFB" /><entity charOffset="308-316" id="DDI-PubMed.20660678.s2.e5" text="RFB" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e0" e2="DDI-PubMed.20660678.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e0" e2="DDI-PubMed.20660678.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e0" e2="DDI-PubMed.20660678.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e0" e2="DDI-PubMed.20660678.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e0" e2="DDI-PubMed.20660678.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e0" e2="DDI-PubMed.20660678.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e1" e2="DDI-PubMed.20660678.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e1" e2="DDI-PubMed.20660678.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e1" e2="DDI-PubMed.20660678.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e1" e2="DDI-PubMed.20660678.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e1" e2="DDI-PubMed.20660678.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e2" e2="DDI-PubMed.20660678.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e2" e2="DDI-PubMed.20660678.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e2" e2="DDI-PubMed.20660678.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e2" e2="DDI-PubMed.20660678.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e3" e2="DDI-PubMed.20660678.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e3" e2="DDI-PubMed.20660678.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e3" e2="DDI-PubMed.20660678.s2.e5" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e4" e2="DDI-PubMed.20660678.s2.e4" /><pair ddi="false" e1="DDI-PubMed.20660678.s2.e4" e2="DDI-PubMed.20660678.s2.e5" /></sentence><sentence text=" The sequence of treatments was randomized, and each treatment period lasted 12 days" /><sentence text=" Full pharmacokinetic profiles were determined for DRV, ritonavir, and RFB and its active metabolite, 25-O-desacetylrifabutin (desRFB), on day 13"><entity charOffset="56-65" id="DDI-PubMed.20660678.s4.e0" text="ritonavir" /><entity charOffset="102-125" id="DDI-PubMed.20660678.s4.e1" text="25-O-desacetylrifabutin" /><entity charOffset="71-93" id="DDI-PubMed.20660678.s4.e2" text="RFB" /><entity charOffset="130-152" id="DDI-PubMed.20660678.s4.e3" text="RFB" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e0" e2="DDI-PubMed.20660678.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e0" e2="DDI-PubMed.20660678.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e0" e2="DDI-PubMed.20660678.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e0" e2="DDI-PubMed.20660678.s4.e3" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e2" e2="DDI-PubMed.20660678.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e2" e2="DDI-PubMed.20660678.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e2" e2="DDI-PubMed.20660678.s4.e3" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e1" e2="DDI-PubMed.20660678.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s4.e1" e2="DDI-PubMed.20660678.s4.e3" /></sentence><sentence text=" The DRV and ritonavir areas under the plasma concentration-time curve from zero to 12 h (AUC(12h)) increased by 57% and 66%, respectively, in the presence of RFB"><entity charOffset="13-22" id="DDI-PubMed.20660678.s5.e0" text="ritonavir" /><entity charOffset="159-167" id="DDI-PubMed.20660678.s5.e1" text="RFB" /><pair ddi="false" e1="DDI-PubMed.20660678.s5.e0" e2="DDI-PubMed.20660678.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20660678.s5.e0" e2="DDI-PubMed.20660678.s5.e1" /></sentence><sentence text=" The RFB exposure was comparable between treatment with RFB QD alone (treatment B) and treatment with DRV/r plus RFB QOD (treatment C); however, based on least-square means ratios, the minimum plasma concentration (C(min)) increased by 64% and the maximum plasma concentration (C(max)) decreased by 28%, respectively"><entity charOffset="5-7" id="DDI-PubMed.20660678.s6.e0" text="RFB" /><entity charOffset="56-58" id="DDI-PubMed.20660678.s6.e1" text="RFB" /><entity charOffset="113-115" id="DDI-PubMed.20660678.s6.e2" text="RFB" /><pair ddi="false" e1="DDI-PubMed.20660678.s6.e0" e2="DDI-PubMed.20660678.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20660678.s6.e0" e2="DDI-PubMed.20660678.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s6.e0" e2="DDI-PubMed.20660678.s6.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s6.e1" e2="DDI-PubMed.20660678.s6.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s6.e1" e2="DDI-PubMed.20660678.s6.e2" /></sentence><sentence text=" The exposure (AUC within the dosage interval and at steady state [AUC(Ï„)]) to desRFB was considerably increased (by 881%) following treatment with DRV/r/RFB"><entity charOffset="82-84" id="DDI-PubMed.20660678.s7.e0" text="RFB" /><entity charOffset="154-156" id="DDI-PubMed.20660678.s7.e1" text="RFB" /><pair ddi="false" e1="DDI-PubMed.20660678.s7.e0" e2="DDI-PubMed.20660678.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20660678.s7.e0" e2="DDI-PubMed.20660678.s7.e1" /></sentence><sentence text=" The exposure to the parent drug plus the metabolite increased 1" /><sentence text="6-fold in the presence of DRV/r" /><sentence text=" Adverse events (AEs) were more commonly reported during combined treatment (83% versus 44% for RFB and 28% for DRV/r); similarly, grade 3-4 AEs occurred in 17% versus 11% and 0%, respectively, of volunteers"><entity charOffset="96-98" id="DDI-PubMed.20660678.s10.e0" text="RFB" /></sentence><sentence text=" Eighteen of 27 volunteers (66" /><sentence text="7%) prematurely discontinued the trial; all volunteers discontinuing for safety reasons (n = 9) did so during RFB treatment phases"><entity charOffset="110-112" id="DDI-PubMed.20660678.s12.e0" text="RFB" /></sentence><sentence text=" These results suggest that DRV/r may be coadministered with RFB with a dose adjustment of RFB to 150 mg QOD and increased monitoring for RFB-related AEs"><entity charOffset="61-63" id="DDI-PubMed.20660678.s13.e0" text="RFB" /><entity charOffset="91-93" id="DDI-PubMed.20660678.s13.e1" text="RFB" /><entity charOffset="138-140" id="DDI-PubMed.20660678.s13.e2" text="RFB" /><pair ddi="false" e1="DDI-PubMed.20660678.s13.e0" e2="DDI-PubMed.20660678.s13.e0" /><pair ddi="false" e1="DDI-PubMed.20660678.s13.e0" e2="DDI-PubMed.20660678.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s13.e0" e2="DDI-PubMed.20660678.s13.e2" /><pair ddi="false" e1="DDI-PubMed.20660678.s13.e1" e2="DDI-PubMed.20660678.s13.e1" /><pair ddi="false" e1="DDI-PubMed.20660678.s13.e1" e2="DDI-PubMed.20660678.s13.e2" /></sentence><sentence text=" Based on the overall safety profile of DRV/r, no dose adjustment of DRV/r is considered to be warranted" /><sentence text=" Given the safety profile seen with the combination of RFB with a boosted protease inhibitor in this and other studies, it is not recommended to conduct further studies with this combination in healthy volunteers"><entity charOffset="55-57" id="DDI-PubMed.20660678.s15.e0" text="RFB" /></sentence><sentence text="" /></document>